McKesson Ventures

McKesson Ventures is the corporate venture capital arm of McKesson Corporation that invests in healthcare technology and services companies across early to growth stages. Based in San Francisco, it seeks minority investments to support digital health and technology-enabled services that improve healthcare delivery for pharma, pharmacy, providers, and patients. The firm targets opportunities in healthcare information technology, health tech, and healthcare systems, with a focus on innovative direct-to-consumer health care and new clinical services, aiming to back ventures that enhance efficiency and care outcomes across the health care economy.

Jennifer Carter

Partner and Vice President Venture Operations

Priyanka Kanal

Associate

Dave Schulte

Managing Director

Michelle Snyder

Partner

Carrie Williams

Vice President

Brian Zhu

Senior Associate

Past deals in Armenia

Vineti

Series C in 2020
Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.